1. Boyd, M. R. 1988. Strategies for the identification of new agents for the treatment of Aids: A national program to facilitate the discovery and preclinical development of new drug candidates for clinical evaluation. In: Aids, Etiology, Diagnosis, Treatment and Prevention, (V.T. Devita, S. Hellman, S.A. Rosenberg, eds.). J.B. Lippincott, Philadelphia. pp. 305–319.
2. Boyd, M. R. 1989. Status of the Nci preclinical antitumor drug discovery screen. In: Ppo Updates, vol.3, no. 10 (V.T. Devita, S. Hellman, S.A. Rosenberg, eds.). J.B. Lippincott, Philadelphia. pp. 1–12.
3. Boyd, M. R. 1993. The future of new drug development. In: Current Therapy in Oncology, (J.E. Niederhuber, ed.). B.C. Decker, Inc., Philadelphia. pp. 11–22.
4. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Boyd, M. 1991. Feasibility of a High-Flux Anticancer Drug Screen Utilizing a Diverse Panel of Human Tumor Cell Lines in Culture. J. Natl. Cancer Inst. 83: 757–766.
5. Boyd, M. R., Paull, K. D., Rubinstein, L. R. 1992. Data display and analysis strategies for the Nci disease-oriented in vitro antitumor drug screen. In: Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, (F.A. Valeriote, T. Corbett, L. Baker, eds.). Kluwer Academic Publishers, Amsterdam. pp. 11–34.